Older adults outnumber children in almost half of US counties: Census data
Older adults now outnumber children in almost half of the counties in the U.S., new data released Thursday from the Census Bureau shows.
About 45 percent of the nation's more than 3,100 counties reported more residents 65 years or older than those under the age of 18 in 2024, according to a press release. This marks a significant increase from four years prior, when just 31.3 percent of the counties had more older adults than children.
Most of the counties with an older population were located outside of the metro or micro areas, the release states.
Overall, the population of residents over the age of 65 increased by 3.1 percent from 2023 to 2024, now around 61.2 million. On the other side, the population under 18 decreased by 0.2 percent over the last year, sitting around 73.1 million, the bureau found.
The share of older adults in the U.S. has steadily increased since 2004, increasing from 12.4 percent in 2004 to 18 percent last year. The population of children has declined, dropping from 25 percent to 21.5 percent in that same timeframe, the data shows.
In 2022, the nation's median age hit 38.9 — the highest it had been at that point. The median age has also been rising for decades, spiking from 30 in 1980 to 35 in 2000.
The latest numbers come as statistics show women in the U.S. having fewer children. Last year, the Centers for Disease Control and Prevention (CDC) released a report showing between 2007 and 2022, the nation's birth rate fell by nearly 23 percent.
'Children still outnumber older adults in the United States, despite a decline in births this decade,' Lauren Bowers, chief of the Census Bureau's Population Estimates Branch, said in Thursday's release.
'However, the gap is narrowing as baby boomers continue to age into their retirement years,' Bowers added. 'In fact, the number of states and counties where older adults outnumber children is on the rise, especially in sparsely populated areas.'
A Census Bureau estimate released in 2023 found that the U.S. population was expected to peak in 2080 and then fall by the end of the century.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Anti-vaccine activist presents data to RFK Jr.'s reshaped CDC advisory panel
A longtime anti-vaccine activist gave a presentation at the Centers for Disease Control and Prevention's vaccine advisory committee meeting Thursday on an issue that has long been considered settled science. It was perhaps the clearest sign of how meetings of the panel, called the Advisory Committee on Immunization Practices, have already changed drastically under Health and Human Services Secretary Robert F. Kennedy Jr., who recently fired all 17 members of the panel and replaced them with a group of his own appointees. The presenter, nurse practitioner Lyn Redwood, is the president emerita of Children's Health Defense, the anti-vaccine group founded by Kennedy. Her presentation focused on thimerosal, a mercury-based preservative that had previously been used in some vaccines. Since 2001, however, nearly all vaccines made in the United States contain no thimerosal or only trace amounts. The exception is the multi-dose flu shot vials, though most flu shots now come in single-dose packaging that doesn't contain the preservative. Anti-vaccine activists have long claimed that thimerosal is linked to autism, but the link has been widely debunked. Redwood referenced 'neurodevelopmental disorders' rather than autism in her presentation, but after the presentation asserted links between thimerosal and brain inflammation, which she called 'one of the hallmarks that we see in autism.' A background briefing document that was available on the CDC's website Tuesday said that a summary of studies found 'no association between prenatal exposure to thimerosal-containing vaccinations and autism spectrum disorder in children.' The document was taken down Wednesday without explanation. ACIP member Dr. Robert Malone said Thursday during the meeting that, based on his understanding, 'that article was not authorized by the Office of the Secretary and has been removed.' Dr. David Higgins, a pediatrician and preventive medicine specialist at the University of Colorado Anschutz Medical Campus, decried the document's removal. 'Decades of evidence were ignored or even hidden,' said Higgins, who wasn't a part of the meeting. 'That's not being transparent. That's not scientific integrity.' Following the presentation, the committee voted 5-1 to recommend that children, adults and pregnant women get single-dose thimerosal-free flu vaccines. One member, Vicky Pebsworth, abstained. Before ACIP recommendations are implemented, the CDC director must sign off on them. However, there is currently no director in place as the nominee for the position, Susan Monarez, awaits confirmation by the Senate. In the absence of a director, Kennedy has the authority to adopt the ACIP's recommendations. ACIP recommendations do not mean the multi-dose vials are banned; for that to happen the Food and Drug Administration would need to revoke approval. Thimerosal-free flu shots account for the majority of the doses given in the U.S. Just 4%-5% of flu vaccines used during the 2024-2025 season were multi-dose, thimerosal-containing vaccines, Tracey Beth Høeg, a special advisor to the FDA commissioner, said during the meeting. Dr. Cody Meissner, a pediatrician, was the lone dissenting vote. 'The risk from influenza is so much greater than the nonexistent, as far as we know, risk from thimerosal,' Meissner said of his vote. 'I would hate for a person not to receive the influenza vaccine because the only available preparation contains thimerosal. I find that very hard to justify.' Meissner had initially followed up Redwood's presentation by saying he wasn't sure how to respond to it. 'This is an old issue that has been addressed in the past,' he said. Multiple infectious disease experts said on a Thursday press call following the ACIP meeting that multi-dose vaccines can be useful for vaccinating large groups such as workers. The decision not to recommend thimerosal-containing vaccines could also dissuade other countries — where multi-dose vials are more common — from using them, thereby reducing vaccine access, they added. Dr. Sean O'Leary, the American Academy of Pediatrics' liaison to ACIP, called Redwood's presentation 'unprecedented.' 'That was a highly-biased presentation full of cherry-picked data and junk science,' O'Leary said. 'The vast majority of it wasn't actually relevant to thimerosal in vaccines.' O'Leary told reporters in a call on Thursday that the AAP chose not to participate in the meeting, which it usually does. 'This meeting showcased an ACIP that has drifted so far from its long-standing focus on science, evidence and public health. When that focus returns, we will, too,' he said. Higgins, the Colorado pediatrician who was not part of the meeting, said, 'it's outrageous that a decision as consequential as this would be decided based on a single presentation from someone who arguably is not an expert in the field.' Redwood's presentation also triggered a slew of responses from representatives of major medical organizations participating in the meeting, who questioned the veracity of the data presented and asked to see credible scientific evidence. 'Will there be an actual CDC presentation done by staff scientists, physicians and those who are subject matter experts with accurate, peer-reviewed scientific data,' Dr. Jason Goldman, American College of Physicians' liaison to ACIP, asked the committee, 'or will we have lay person presentations only?' Committee Chair Martin Kulldorff, a biostatistician who has criticized pandemic lockdowns and Covid vaccines, scolded those representatives for their pushback. 'I think it's inappropriate to dismiss a presentation just because the person does not have a Ph.D., or an MD,' he said. 'There are a lot of knowledgeable people who we would like to hear from, and we want to hear from a variety of viewpoints. And I think today's discussion is a very good example that we have received input from a variety of people on this topic.' In a separate vote, the committee reaffirmed the existing recommendation that people ages 6 months and older should get annual flu shots, with six votes in favor. Pebsworth again chose to abstain. Earlier Thursday, the committee voted on whether to recommend an RSV drug for infants younger than 8 months. Five members voted in favor and two voted against, providing the majority vote needed for the recommendation to pass. The drug up for a vote Thursday, clesrovimab, is a monoclonal antibody injection that can prevent lower respiratory disease in infants during or before their first RSV season, which typically starts in the fall and peaks in the winter. RSV leads to up to 300 deaths a year among those younger than 5 in the U.S. A dramatic spike in severe RSV overwhelmed children's hospitals in late 2022. Clesrovimab was approved by the Food and Drug Administration earlier this month. A similar drug, nirsevimab, has also been approved for infants and some young children since 2023. A vaccine for pregnant women that also protects newborns is approved as well. Meissner, who was part of the committee's work group on RSV, fielded questions from fellow members about the trial data and the disease itself. He explained how newborns' tiny airways put them at higher risk for severe illness. That risk, he said, falls in their second year of life, when the airways are larger. The work group determined that the drug was effective at preventing severe RSV in young infants and had a favorable safety profile. 'These are truly remarkable products. They are safe and they're effective,' Meissner said. 'The FDA has spent an enormous amount of time looking at safety and efficacy.' Despite this, two members of the group, Retsef Levi and Vicky Pebsworth, questioned the drug's safety and voted not to recommend it. This article was originally published on
Medscape
2 hours ago
- Medscape
ACIP's New Class Endorses RSV, Talks COVID
A second monoclonal antibody to prevent respiratory syncytial virus (RSV) in infants has been recommended by the CDC's Advisory Committee on Immunization Practices (ACIP). Five voting members said no to recommending clesrovimab, a recently approved monoclonal antibody, for prevention of RSV in newborns and infants, based on safety concerns. Clesrovimab joins nirsevimab, a long-acting monoclonal antibody approved in 2023, in the arsenal to help protect infants and children against RSV. RSV remains a substantial burden among children younger than 5 years of age in the United States, and in the absence of prevention products, approximately 97% of infants develop RSV infections before age 2 years, said Adam MacNeil, PhD, of the CDC's National Center for Immunization and Respiratory Diseases, in his presentation. The current strategies for prevention of RSV in children and pregnant women are safe and effective, and the addition of a second option for children should increase access and address issues of supply, said MacNeil. Clesrovimab was recently approved by the FDA for prevention of RSV in infants younger than 8 months of age who were born during or entering their first RSV season. The ACIP previously recommended nirsevimab for prevention of RSV in this population and in children aged 8-19 months at increased risk of severe RSV disease and entering their second RSV season. For pregnant women, the CDC and ACIP continue to recommend a single dose of RSV vaccine (ABRYSVO) between 32 and 36 weeks' gestation. The development of monoclonal antibody products to prevent RSV in infants is 'a spectacular accomplishment,' said ACIP Panelist Cody Meissner, MD, a professor of pediatrics at Dartmouth Geisel School of Medicine, Hanover, New Hampshire, in a comment during the meeting. Providing data from clinical trials to inform recommendations 'is something the CDC does very well,' he said. The majority the public commentators during the first day of the meeting were clinicians who expressed support for the safety and effectiveness of vaccines. 'I have seen what vaccine preventable diseases can do to children,' said Caroline Brown, MD, a pediatrician in private practice in North Carolina, during the public comment. Thanks to vaccines, most children today are spared devastating outcomes, she said. However, Brown noted that she has been fielding calls from panicked parents with the appearance of measles in her area and emphasized that approved vaccines for children, including the measles vaccine, have been extremely well-researched and found to be safe and effective. Keeping the RSV Prevention Momentum Going Continued recommendation of the RSV vaccine is important, as the availability of both maternal vaccines and infant monoclonal antibodies for the past two seasons have resulted in reductions in hospitalizations and outpatient RSV visits, said Lori Handy, MD, MSCE, associate director of the Vaccine Education Center at the Children's Hospital of Philadelphia, Pennsylvania, and assistant professor of clinical pediatrics at the Perelman School of Medicine, in an interview. 'As all infants are at risk of RSV infection, multiple prevention products ensure that all families can access prevention and make informed choices about which prevention is best for their own circumstances,' said Handy. 'Continuing to offer safe and effective preventive options in the forms of maternal vaccines and infant monoclonal antibodies will ensure the success of the past two seasons will be enjoyed for newborns to come,' she emphasized. When it comes to vaccine information, clinicians continue to be the most trusted messengers, Handy told Medscape. Clinicians are in the best positions to have conversations with families and provide a strong recommendation to choose either maternal vaccine or monoclonal antibody for RSV prevention, she said. 'Direct patients and families to trusted resources developed by organizations with long-standing commitments to protecting the health of mothers and infants, such as ACOG, the Vaccine Education Center, and the American Academy of Pediatrics,' Handy added. The AMA Weighs In In advance of the ACIP meeting, the American Medical Association (AMA) posted an open letter to the American people with its position on respiratory vaccines. The letter acknowledged concerns in the medical and public health communities about the recent upheaval in ACIP membership and called on physicians to continue to provide 'clear, evidence-based guidance' to patients. 'We commit to working together to promote public understanding and confidence in the use of vaccines to avoid another severe respiratory virus season and resurgence of vaccine-preventable illnesses and deaths,' the AMA said in the statement. COVID-19 Here to Stay Although no voting related to COVID-19 vaccination occurred, the meeting began with a review of the latest data on COVID-19 epidemiology, followed by safety and efficacy reviews of former and current versions of the vaccine and a summary of the CDC's current recommendations. MacNeil noted in a separate presentation that although COVID-19 rates have decreased over the past several years, cumulative rates remain high among adults aged 75 years and older. He also noted that the risk of hospitalization from COVID-19 persists year-round, especially in vulnerable populations.
Yahoo
2 hours ago
- Yahoo
Robert F. Kennedy Jr. Tells Fox News The Rotten Truth About His Anti-Fluoride Crusade
Robert F. Kennedy Jr. admitted on Thursday there are some potentially big holes in his decision to stop recommending water fluoridation nationwide ― as in cavities. During an interview on Fox News, host Harris Faulkner asked the conspiracy theory-peddling health and human services secretary to address concerns from America's dental community about lower-income children who might not be getting preventative dental care. Kennedy admitted there would be trade-offs for getting rid of fluoride in water. 'It's a balance,' he said. 'You're gonna see probably slightly more cavities. Although in Europe, where they banned fluoride, they did not see an uptick in cavities. The issue is, parents need to decide, because science is very clear on fluoride.' Many years of research show that water fluoridation can significantly reduce cavities in both children and adults, and the U.S. Centers for Disease Control and Prevention has hailed it as one of the country's 10 greatest health achievements of the 20th century. Kennedy, however, has railed against it. He said in April that when it comes to fluoride, 'the more you get, the stupider you are,' referencing a 2025 journal article that suggested fluoride might lower IQs in children. The authors of that study have said themselves that their findings should not be used to evaluate the use of fluoride in water in the U.S., for a variety of reasons. Kennedy was also wrong when he suggested that Europe as a whole had banned fluoride in water. While it's true that many European countries do not add it to their water, the region has a patchwork of practices, as outlined by a 2018 report. Some parts of the U.K. and Ireland fluoridate their tap water, while Greece adds it to bottled water. And in some areas, fluoride occurs naturally in the water supply. Thus far in the U.S., Kennedy's push has led Florida and Utah to ban water fluoridation. Here's a clip of the exchange: Because the science is very clear that water fluoridation can prevent cavities, and because oral hygiene affects overall health, many people mocked Kennedy for minimizing the potential effects of his anti-fluoride crusade, which is expected to harm low-income children the most. One person snarkily saw an upside to RFK Jr.'s anti-fluoride push. DeSantis Signs Bill Banning Fluoride From Florida's Water System FDA, RFK Jr. Begin Effort To Remove Ingestible Fluoride Products From Market RFK Jr. On Fluoride: 'The More You Get, The Stupider You Are' Republicans Are Lending Support To 1 Of RFK Jr.'s False Claims
